Clinical trials: BACTERIAL VAGINOSIS
Bacterial Vaginosis
Lcr35® for Bacterial Vaginosis Prevention
This is a national, multi-centre, randomized, double-blind placebo-controlled, phase III superiority trial. The main objective of the trial is to assess the efficacy of Lcr35® by comparing the mean time before the onset of the…
- Trial name
- NCT01160796
- Testing
- Lcr35®
- Where
- France
- Volunteers
- 352 people
- Sponsor
- Laboratoires Lyocentre
Recurrent Vulvovaginal Candidiasis
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Pevion Biotech develops a state-of-the-art vaccine against recurrent vulvovaginal candidiasis (RVVC) caused by the pathogenic form of Candida albicans especially in pre-menopausal women of childbearing age with a history of…
- Trial name
- NCT01067131
- Testing
- PEV7C1, PEV7C9, PEV7B2
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Pevion Biotech Ltd
Bacterial Vaginosis
PreFem: "What Happens to the Vaginal Microbiota When a BV Infection is Treated With Metronidazole?"
The study will assess vaginal microbiota levels before and after antibiotic treatment in females infected with Bacterial Vaginosis (BV).
- Trial name
- PreFem (NCT03187457)
- Testing
- Metronidazole, Control: no treatment
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Danisco
Bacterial Vaginosis
Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
This research study is being done to compare the safety and efficacy of GDC-229 (test drug) against the currently marketed reference drug (metronidazole 0.75% vaginal gel) and to establish that these two drugs work better than…
- Trial name
- NCT03091777
- Testing
- GDC-229, Metronidazole Vaginal Gel 0.75%
- Where
- United States
- Volunteers
- 871 people
- Sponsor
- Balmoral Medical company
Bacterial Infections, Bacterial Infections and Mycoses
Large Algorithm Setting and Validation Study
In this pilot study, prospectively acquired clinician-collected and participant-collected vaginal swab specimens will be obtained from up to 1000 individuals with signs and symptoms of vaginitis to develop and validate a…
- Conditions
- Bacterial Infections, Bacterial Infections and Mycoses, Infections, Vaginitis
- Trial name
- LAVA (NCT07607470)
- Testing
- Nanopath Vaginitis Assay, BD Max™ Vaginal Panel, Cepheid Xpert® Xpress MVP
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Nanopath, Inc
Bacterial Vaginosis
GoldenCareTM for the Treatment of Bacterial Vaginosis
GoldenCare is a copper intravaginal device that may be useful for the treatment of symptomatic bacterial Vaginosis (BV). Standard treatment for BV is metronidazole.
- Trial name
- NCT01762670
- Testing
- GoldenCare, Metronidazole
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- CDA Research Group, Inc.
Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC)
Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis
This study aims to compare the efficacy and safety of the combination drug Clotrimazole+Lactulose with the monocomponent product Canesten® (clotrimazole) in adult women diagnosed with candidal vulvovaginitis.
- Trial name
- NCT06835361
- Testing
- Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose
- Where
- 7 sites in Belarus, Russia
- Volunteers
- 264 people
- Sponsor
- AVVA Pharmaceuticals Ltd.
Vaginosis, Bacterial, Candidiasis, Vulvovaginal
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
This is a study to compare the safety and efficacy of the use of a intravaginal ovule containing a combination of Ketoconazole and Clindamycin to the use of an intravaginal cream containing a combination Tetracycline and…
- Trial name
- NCT01293643
- Testing
- 100 mg clindamycin /800 mg ketoconazole vaginal ovule, 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Vulvovaginal Candidiasis
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
This is a multi-center, randomized, double-blind, placebo-controlled study intended to assess the safety, tolerability and humoral and cellular immune response over a 12-month period after receiving one dose of either the NDV-3A…
- Trial name
- NCT01926028
- Testing
- NDV-3A, NDV-3
- Where
- 20 sites in United States
- Volunteers
- 188 people
- Sponsor
- NovaDigm Therapeutics, Inc.
Vulvovaginal Candidiasis, Genital
Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis
The purpose is to study superior efficacy of combination of Natamycin and Lactulose (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin 100 mg vaginal suppositories), or Lactulose 300 mg…
- Trial name
- NCT06411314
- Testing
- Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories, Lactulose 300 mg vaginal suppositories, Pimafucin® (natamycin) 100 mg vaginal suppositories
- Where
- Russia
- Volunteers
- 218 people
- Sponsor
- Avva Rus, JSC
Bacterial Vaginosis
DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC Universal Placebo Gel) (QD × 1 day) for the treatment…
- Trial name
- NCT04370548
- Testing
- DARE-BV1clindamycin phosphate vaginal gel, 2%
- Where
- 10 sites in United States
- Volunteers
- 307 people
- Sponsor
- Daré Bioscience, Inc.
Bacterial Vaginosis
A Pilot Study to Evaluate the Efficacy and Safety of Lactobacillus Species Suppositories on Vaginal Health and pH
Most of the methods involved in the treatment of BV include antibiotics. Some of the antibiotics used for this include metronidazole, clindamycin and fluconazole. The antibiotics inhibit the growth of anaerobes that support G.
- Trial name
- NCT05060029
- Testing
- Lactobacillus Species
- Where
- 5 sites in India
- Volunteers
- 75 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Vulvovaginal Candidiasis
VVC Sampling Study for Analysis Validation
This is a biomarker multi-centre study to validate an extraction method of fungal and bacterial DNA extracted from vaginal swabs from adult women with confirmed VVC.
- Trial name
- NCT05327192
- Testing
- No intervention, only sampling
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- Gedea Biotech AB
Bacterial Vaginosis
Live Double Combined Lactobacillus Capsule for Vaginal Use(IIb)
This is a multicenter, randomized, double-blind, placebo-controlled phase IIb clinical study, to evaluate the efficacy and safety of the dual - live Lactobacilli-containing vaginal capsule for the treatment of bacterial vaginosis.
- Trial name
- BV (NCT07418918)
- Testing
- Vaginal Lactobacillus Dual Probiotic Capsules
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Guangdong Longchuangji Pharmaceutical Co., Ltd.
Bacterial Vaginosis
Analysis of Ameliorative Effects of Oral Probiotics on Bacterial Vaginosis
The purpose of this study is to analyze the ameliorative effects of oral probiotics on bacterial vaginosis.
- Trial name
- NCT03116789
- Testing
- probiotics
- Where
- Taiwan
- Volunteers
- 43 people
- Sponsor
- GenMont Biotech Incorporation
Bacterial Vaginosis
Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis
The purpose of this clinical study was to evaluate whether vaginal tablets containing 10 mg dequalinium chloride (Fluomizin) are comparable in clinical efficacy and safety to clindamycin vaginal cream (2%) in patients suffering…
- Trial name
- NCT01125410
- Testing
- Dequalinium chloride, Clindamycin
- Where
- 14 sites in Belgium, Czechia and 3 more
- Volunteers
- 321 people
- Sponsor
- Medinova AG
Vaginal Candidiasis, Bacterial Vaginosis
Observational Program Neo-Penotran® Forte
Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or…
- Conditions
- Vaginal Candidiasis, Bacterial Vaginosis, Trichomonal Vaginitis
- Trial name
- NCT01335373
- Testing
- Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
- Where
- Kazakhstan
- Volunteers
- 13,024 people
- Sponsor
- Bayer
Pregnancy
The Effect of Probiotics on Maintenance of Health in Pregnancy and Infants
This phase 2 study evaluates the effect of perinatal use of probiotics on the number of diagnosed viral, bacterial and fungal infections in pregnant women and on the maintenance of a health pregnancy.
- Trial name
- NCT03310853
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Candida Vulvovaginitis
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus oral fluconazole in adult female subjects 18 years and…
- Trial name
- DOVE (NCT03253094)
- Testing
- Fluconazole, SCY-078
- Where
- 25 sites in United States
- Volunteers
- 186 people
- Sponsor
- Scynexis, Inc.
Bacterial Vaginosis, Vulvovaginal Candidiasis
TOL-463 Phase 2 Study for Vaginitis
This is a Phase II study designed to assess the safety and efficacy of an investigational product, TOL-463, to treat vaginitis.
- Trial name
- NCT02866227
- Testing
- TOL-463
- Where
- 2 sites in United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Toltec Pharmaceuticals, LLC